MKManjit Kaur

Manjit Kaur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manjit Kaur has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatments for Pyoderma Gangrenosum: A Systematic Review and Single‐Arm Meta‐Analysis of Systemic Therapies

    by Manjit Kaur, Michael J. Diaz, Michelle Anthony, Dana Jolley, Anna H. Schildmeyer, Jacob McFeeters, Benjamin H. Kaffenberger

    Pyoderma gangrenosum (PG) is a neutrophilic dermatosis associated with significant morbidity and mortality, with no consensus treatment to date. To review all clinical trials of treatments for PG to synthesise clinical evidence regarding the efficacy and safety of different treatments. After PROSPERO (CRD42023459180) registration, we systematically searched five databases (clinicaltrials.gov, CENTRAL, Embase, PubMed and Scopus) up until 18th May 2024 for PG treatments. Of 10 579 identified articles, 5853 deduplicated abstracts were screened. Twenty studies met the screening criteria after a full text review of 60 articles. We assessed the risk of bias using ROBIN‐I for non‐randomised and ROB‐2 for randomised trials. Two reviewers independently performed article screening and quality assessments. Two reviewers independently extracted and recorded data on study characteristics, participants' demographics, disease characteristics, treatment regimens, and outcomes for the selected studies. A single‐arm meta‐analysis of available RCTs and non‐randomised studies was conducted to analyse the outcomes of different systemic immunomodulators. The primary outcome was the complete healing of PG. Secondary outcomes included rates of recurrence, treatment failure, adverse events and time to complete healing. A total of twenty (20) interventional studies were included in the data synthesis: nine (9) prospective open‐label studies, six (6) prospective cohort studies, three (3) open‐label clinical trials, and two (2) randomised controlled trials evaluating multiple biological, systemic, and topical interventions. On random effects meta‐analysis of systemic therapies including adalimumab, canakinumab, infliximab, chlorambucil, cyclosporine, cyclophosphamide and prednisolone, the pooled proportion of complete healing across 11 studies was 0.59 (95% confidence interval [CI]: 0.41–0.74; Χ2 = 26.66, p < 0.01; I2 = 66%); the pooled proportion of PG recurrence across 6 studies was 0.30 (95% CI: 0.20–0.41; Χ2 = 1.14, p = 0.95; I2 = 0%); the pooled proportion of serious adverse effects from 4 studies was 0.10 (95% CI: 0.05–0.19; Χ2 = 5.01, p = 0.17; I2 = 40%); and the pooled proportion of PG treatment failure across seven studies was 0.36 (95% CI: 0.24–0.49; Χ2 = 12.78, p = 0.03; I2 = 61%). The proportion of complete wound healing varies significantly across treatments and recurrence is common even in a limited follow‐up period. Heterogeneity of study methods and low numbers hamper disease research. There remains a significant unmet need for better outcome measures than just complete healing as well as better treatment options to improve patient outcomes.


  • Open Access

    SARS-COV-2-19 Diagnosis Through Integration of Thermal Video and Patient Data

    by Manjit Kaur, Stephanie Trovato, Lynn Fussner, Christina Liscynesky, Bing Zha, Alper Yilmaz, Benjamin Kaffenberger

    INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic rapidly spread across the world, creating a need for real-time screening of individuals to prevent further transmission. We aimed to develop a mobile thermographic imaging platform, intended to scan an entrance or hallway to identify people with abnormal facial temperatures and/or vital signs. METHODS: Adult patients who were actively symptomatic with SARS-CoV-2 infection were included along with people with other febrile illnesses, such as pneumonia or viral infection, and healthy/asymptomatic individuals, for comparison. We applied an attention-based model to conduct a thermal image-based diagnosis of the disease. Thermographic images and videos of the study subjects were obtained through a hand-held thermal camera at distances of 5 and 10 feet. Subsequently, the videos were processed and analyzed in the Photogrammetric Computer Vision Laboratory to attempt to categorize individuals with abnormal facial temperatures and vital signs. RESULTS: Out of a total of 76 participants, 35 patients were positive for SARS-CoV-2 with active infectious syndromes, 21 were diagnosed with other infectious diseases, and the remaining 20 were asymptomatic control subjects. The dataset consists of short videos recorded by the thermal camera to indicate the temperatures of the participants. 53 videos were obtained for SARS-CoV-2 patients and 22 for non-SARS-CoV-2 patients, where 15 frames are sampled from each video at an equal distance, and each frame is resized as 224 pixels. CONCLUSIONS: This study generated preliminary methods and results aimed at the early identification of febrile illness and can be used as a baseline for future research.

  • Apremilast for Recalcitrant Cutaneous Dermatomyositis: A Review of Current Literature

    by Manjit Kaur, Jessica Kaffenberger, Judith Lin, Abraham M. Korman

  • Open Access

    Clinical Characteristics, Treatments, and Outcomes of Pyoderma Gangrenosum of the Face: A Systematic Review

    by Manjit Kaur, Michelle R. Anthony, Coleman Yamakoshi, Anna Schildmeyer, Teja Mallela, Michael J. Diaz, Salma Shire, Benjamin H. Kaffenberger


  • Correlation of pyoderma gangrenosum activity with fecal calprotectin levels- a retrospective cohort study

    by Manjit Kaur, Jacob McFeeters, Divyaam Satija, Jacob M. Skeans, Antoinette Pusateri, Abraham M. Korman, Benjamin H. Kaffenberger


  • Open Access

    Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care

    by Connie R. Shi, Alana L. Ferreira, Manjit Kaur, David Xiang, Jean Caputo, Hannah K. Choe, Nada Hamad, Edward W. Cowen, Benjamin H. Kaffenberger, Emily Baumrin


  • Open Access

    Smashed skin grafting in stable vitiligo: Efficacy and safety

    by Manjit Kaur, Suresh Kumar Malhotra

    Background: Vitiligo is a common skin disorder that entails cosmetic disfigurement due to depigmentation and carries a social stigma. Smash grafting is an easy-to-master surgical treatment modality for stable vitiligo that has failed to respond to other treatments. The technique involves procuring a thin skin graft from a donor site, smashing it into the thinnest possible pieces, and grafting the smash onto the dermabraded vitiligo site. Objective: To analyze the efficacy and safety of smash grafting in patients with stable vitiligo. Materials and Methods: Thirty patients underwent smash grafting in stable recalcitrant vitiligo lesions. The patients were randomly placed in groups A and B. Group A received PUVASOL therapy postprocedure, while group B received only sunlight exposure after smash grafting. The patients were followed up every month for 3 months to assess repigmentation of the grafted site compared to the patient’s normal skin color. Results: Repigmentation was noticed at the grafted site starting as early as 3 weeks postprocedure in all the patients, and an increase in pigmentation intensity was observed until the end of the study follow-up. At the end of the 3-month follow-up, 76.66% of the patients had regained 50% or more pigmentation of the involved lesion. Conclusion: Smash grafting provided excellent repigmentation in >75% of patients without any significant complications. It is a simple and effective surgical technique that is underutilized. Furthermore, this procedure is less resource-intensive and easier to master than other surgical techniques for vitiligo.

  • Open Access

    Study Protocol: Autologous Platelet-Rich Plasma (PRP) Therapy in the Treatment of Pyoderma Gangrenosum: A Prospective, Open-Label, Randomized, Split-Ulcer Trial to Evaluate the Efficacy of Platelet-Rich Plasma Therapy in the Treatment of Chronic Pyoderma Gangrenosum

    by Manjit Kaur, Desmond Shipp, Brittany Dulmage, Benjamin H. Kaffenberger

    BACKGROUND Pyoderma gangrenosum (PG) presents as an ulceration of the lower extremities with deep, undermining, and violaceous borders. The disease is an orphan disease without any FDA-approved treatments. OBJECTIVE This study aims to evaluate the efficacy and safety of intralesional injectable and topical platelet-rich plasma (PRP) therapy in the treatment of chronic pyoderma gangrenosum ulcerations. METHODS Methodologically, this study will be conducted as a prospective, randomized, open-label split-ulcer study in patients with confirmed PG by PARACELSUS score. In each patient, up to three separate ulcerations will be randomized to receive either monthly intralesional PRP injections or a topical PRP solution at 0, 4, 8, and 12 weeks, while the third target lesion will receive standard wound care only. Patients will be followed up with at 16 weeks, one month after the completion of treatment. The primary endpoint for this study will be the composite proportion of the target ulcers achieving either complete resolution or a 50% reduction in the surface area at week 12. CONCLUSIONS This study intends to demonstrate the efficacy of an intralesional injectable or topical PRP therapy in the treatment of PG. If successful, PRP treatment may offer a new and effective option for patients with this debilitating disease.

  • Topical Corticosteroid Powder for Peristomal Pyoderma Gangrenosum: A Systematic Review

    by Manjit Kaur, Benjamin Kaffenberger

    Background. Peristomal pyoderma gangrenosum (PPG) is a critical complication after surgical ileostomy or colostomy placement. While topical treatments are often effective, most of the available vehicles reduce ostomy pouch adhesion. There are no commercially available corticosteroid powders for topical application; however, using powder from crushed corticosteroid tablets or capsules may circumvent this issue. Objective. To evaluate the safety and efficacy of topical corticosteroid powders to treat PPG. Methods. This review was registered with the international prospective register of systematic reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Scopus, and Embase databases were searched from inception to October 23, 2023, using keywords "crushed", "powdered", "tablets", "capsules", and "pyoderma gangrenosum." Results. Of 54 results identified, 5 studies comprising 3 case reports and 2 case series met the eligibility criteria. Risk of bias was assessed using Joanna Briggs Institute critical appraisal checklists. The 5 studies included a total of 13 patients. Twelve of 13 patients (92.3%) achieved complete wound healing, a decrease in pain, and improved pouch adherence. No side effects were reported. Conclusion. Crushed corticosteroid tablets and powder from capsules are potentially useful forms of topical therapy for PPG because of their efficacy and ability to facilitate pouch adhesion. However, there is limited evidence, and future randomized clinical trials are necessary to confirm the findings.